Radiopharmaceuticals developed for 89Zr-Immuno-PET
Articles > Article ยท 2021
Authors: Burcu Altiparmak Gulec, Fatma YURT
Journal of Radioanalytical and Nuclear Chemistry, Journal Indexed in SCI Expanded, International, WoS, 2021, vol 330, pp 1-13
DOI: 10.1007/s10967-021-07922-6
Summary
The development of molecular imaging agents used for imaging of cancer tissue is of great importance for the early detection of cancer. Positron emission tomography (PET) radiopharmaceuticals consists of a positron-emitting radionuclide and a molecularstructure. Zr-89-labeled monoclonal antibodies (mAbs), peptides, nanoparticles, proteins, and other compounds are called Zr-89-Immuno-PET and are used in cancer tissue imaging. This review provides a general overview of the potential of molecules labeled with Zr-89 radionuclide, which is chosen due to its long half-life, in preclinical and clinical studies. In light of these studies, radiopharmaceuticals created using nanoparticles have greater potential than those using antibodies.